News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
860,847 Results
Type
Article (87428)
Company Profile (760)
Press Release (772637)
Multimedia
Podcasts (172)
Webinars (28)
Section
Business (233053)
Career Advice (4139)
Deals (39795)
Drug Delivery (136)
Drug Development (91248)
Employer Resources (203)
FDA (18283)
Job Trends (17399)
News (397387)
Policy (39926)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (125)
Alliances (56979)
ALS (145)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (243)
Approvals (18304)
Artificial intelligence (487)
Autoimmune disease (73)
Automation (25)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (159)
Biotechnology (484)
Bladder cancer (132)
Brain cancer (52)
Breast cancer (501)
Cancer (3945)
Cardiovascular disease (339)
Career advice (3556)
Career pathing (38)
CAR-T (246)
CDC (57)
Cell therapy (682)
Cervical cancer (33)
Clinical research (75492)
Collaboration (1381)
Company closure (4)
Compensation (938)
Complete response letters (59)
COVID-19 (2956)
CRISPR (81)
C-suite (587)
Cystic fibrosis (135)
Data (4446)
Decentralized trials (2)
Denatured (61)
Depression (110)
Diabetes (452)
Diagnostics (7091)
Digital health (36)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (230)
Drug pricing (190)
Drug shortages (36)
Duchenne muscular dystrophy (203)
Earnings (98792)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (132968)
Executive appointments (988)
FDA (20738)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (1251)
Gene editing (173)
Generative AI (48)
Gene therapy (545)
GLP-1 (1020)
Government (5384)
Grass and pollen (7)
Guidances (341)
Healthcare (20937)
HIV (48)
Huntington's disease (37)
IgA nephropathy (62)
Immunology and inflammation (242)
Immuno-oncology (20)
Indications (53)
Infectious disease (3193)
Inflammatory bowel disease (187)
Inflation Reduction Act (15)
Influenza (97)
Intellectual property (187)
Interviews (815)
IPO (17926)
IRA (59)
Job creations (5197)
Job search strategy (2865)
Kidney cancer (16)
Labor market (77)
Layoffs (640)
Leadership (33)
Legal (10148)
Liver cancer (91)
Longevity (12)
Lung cancer (568)
Lymphoma (265)
Machine learning (30)
Management (66)
Manufacturing (635)
MASH (138)
Medical device (14869)
Medtech (14892)
Mergers & acquisitions (22745)
Metabolic disorders (1152)
Multiple sclerosis (137)
NASH (23)
Neurodegenerative disease (227)
Neuropsychiatric disorders (60)
Neuroscience (2711)
NextGen: Class of 2025 (7687)
Non-profit (5096)
Now hiring (57)
Obesity (557)
Opinion (312)
Ovarian cancer (133)
Pain (165)
Pancreatic cancer (171)
Parkinson's disease (242)
Partnered (30)
Patents (416)
Patient recruitment (310)
Peanut (57)
People (66252)
Pharmaceutical (144)
Pharmacy benefit managers (27)
Phase I (23282)
Phase II (32767)
Phase III (24689)
Pipeline (2714)
Policy (295)
Postmarket research (3554)
Preclinical (10496)
Press Release (72)
Prostate cancer (200)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (671)
Real estate (7421)
Recruiting (78)
Regulatory (28003)
Reports (65)
Research institute (2689)
Resumes & cover letters (651)
Rett syndrome (16)
RNA editing (15)
RSV (70)
Schizophrenia (135)
Series A (207)
Series B (156)
Service/supplier (30)
Sickle cell disease (79)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4318)
State (2)
Stomach cancer (17)
Supply chain (100)
Tariffs (95)
The Weekly (109)
Vaccines (1044)
Venture capital (66)
Weight loss (396)
Women's health (58)
Worklife (21)
Date
Today (172)
Last 7 days (663)
Last 30 days (2438)
Last 365 days (33525)
2025 (26383)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (80)
Alaska (7)
Arizona (302)
Arkansas (14)
Asia (50972)
Australia (8956)
California (9426)
Canada (2855)
China (899)
Colorado (400)
Connecticut (422)
Delaware (270)
Europe (117104)
Florida (1390)
Georgia (315)
Hawaii (3)
Idaho (67)
Illinois (811)
India (51)
Indiana (460)
Iowa (19)
Japan (323)
Kansas (124)
Kentucky (38)
Louisiana (20)
Maine (77)
Maryland (1275)
Massachusetts (7107)
Michigan (313)
Minnesota (563)
Mississippi (4)
Missouri (119)
Montana (33)
Nebraska (26)
Nevada (107)
New Hampshire (77)
New Jersey (2620)
New Mexico (32)
New York (2572)
North Carolina (1410)
North Dakota (10)
Northern California (4259)
Ohio (295)
Oklahoma (22)
Oregon (50)
Pennsylvania (1963)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (49)
South Dakota (1)
Southern California (3602)
Tennessee (149)
Texas (1476)
United States (34898)
Utah (282)
Virginia (248)
Washington D.C. (83)
Washington State (817)
West Virginia (4)
Wisconsin (97)
Wyoming (1)
There are 860,847 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug
Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.
October 20, 2025
·
2 min read
·
Heather McKenzie
Press Releases
PumasAI Named Best Clinical Pharmacology Tech Innovator 2025 by Global Health and Pharma for the Second Year in a Row
October 20, 2025
·
1 min read
Press Releases
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
· Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers · First-in-class multi-checkpoint inhibitor with robust efficacy and safety · Combination arm with pembrolizumab (Keytruda®) in Australia near to completion by end 2025
October 20, 2025
·
1 min read
Press Releases
Adaptimmune Announces Delisting from Nasdaq
October 20, 2025
·
6 min read
Press Releases
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
October 20, 2025
·
5 min read
Press Releases
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within two weeks of initial treatment --
October 20, 2025
·
6 min read
Lung cancer
Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout, according to Truist analysts, who noted that “OS is likely to be statistically significant” in favor of the PD-1/VEGF bispecific.
October 20, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Rumors of Eli Lilly Buyout Sends Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Approvals
Novo Secures Cardiovascular Expansion for Semaglutide Pill
Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events in at-risk patients with type 2 diabetes.
October 20, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Glaukos Notches FDA Nod for Rare Eye Disorder Keratoconus
Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the drug early next year.
October 20, 2025
·
1 min read
·
Tristan Manalac
1 of 86,085
Next
